Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.11.04.515043v1?rss=1

Authors: Roman-Fernandez, A., Mansour, M., Kugeratski, F. G., Anand, J., Sandilands, E., Galbraith, L., Rakovic, K., Freckmann, E. C., Cumming, E. M., Park, J., Nikolatou, K., Lilla, S., Shaw, R., Strachan, D., Mason, S., Patel, R., McGarry, L., Katoch, A., Campbell, K., Nixon, C., Miller, C. J., Leung, H. Y., Le Quesne, J., Norman, J. C., Zanivan, S. R., Blyth, K., Bryant, D. M.

Abstract:
The glycocalyx component and sialomucin Podocalyxin (PODXL) is required for normal tissue development by promoting apical membranes to form between cells, triggering lumen formation. Elevated PODXL expression is also associated with metastasis and poor clinical outcome in multiple tumour types. How PODXL presents this duality in effect remains unknown. We identify an unexpected function of PODXL as a decoy receptor for Galectin-3 (GAL3), whereby the PODXL-GAL3 interaction releases GAL3 repression of integrin-based invasion. Differential cortical targeting of PODXL, regulated by ubiquitination, is the molecular mechanism controlling alternate fates. Both PODXL high versus low surface levels occur in parallel subpopulations within cancer cells. Orthotopic intraprostatic xenograft of PODXL-manipulated cells or those with different surface levels of PODXL define that this axis controls metastasis in vivo. Clinically, interplay between PODXL-GAL3 stratifies prostate cancer patients with poor outcome. Our studies define the molecular mechanisms and context in which PODXL promotes invasion and metastasis.

Copy rights belong to original authors. Visit the link for more info

Podcast created by Paper Player, LLC